RxDoctor Payments DataLook up a doctor →

Alex Gonzalez Bossolo, MD

Endocrinology, Diabetes & Metabolism · San Juan, PRNPI 1457606444

Payments from drug & device makers

$5,507,348in general payments, 2019–2025

Across 937 payments — averaging $5877.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly Export S.A. Puerto Rico Branch$3.3M
  • Amgen$2M
  • Novartis$93K
  • Lilly USA, LLC$69K
  • Eli Lilly$51K
  • Pfizer$11K
  • plus $17K from 20 others
$76,258in research payments, 2019–2025

Across 15 payments — averaging $5083.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly Export S.A. Puerto Rico Branch$43K
  • Eli Lilly$33K

What the payments were for

  • Consulting fees$2,2842%
  • Speaking & faculty fees$81,35074%
  • Travel & lodging$5,8485%
  • Food & beverage$20,35419%
  • Education$1170%
  • Gifts$590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,507,348 in reported general payments places this provider in the 95th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

See all endocrinology, diabetes & metabolism providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$35,083
Medicare patients
120
Services billed
378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide1,309$1,292,482
MounjaroTirzepatide742$828,912
TrulicityDulaglutide665$716,003
Xigduo XrDapaglifloz Propaned/Metformin531$491,296
JardianceEmpagliflozin518$467,846
FarxigaDapagliflozin Propanediol545$430,538
Synjardy XrEmpagliflozin/Metformin Hcl392$353,129
Trijardy XrEmpaglifloz/Linaglip/Metformin299$306,954
SynthroidLevothyroxine Sodium1,585$117,852
RybelsusSemaglutide89$89,061
Janumet XrSitagliptin Phos/Metformin Hcl94$82,296
Soliqua 100-33Insulin Glargine/Lixisenatide75$67,551
KerendiaFinerenone53$56,939
SynjardyEmpagliflozin/Metformin Hcl67$51,008
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog62$49,365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Humulin 70-30$69,081$1,583,2031,680 claims
Novo NordiskOzempic, Rybelsus$1,522$1,381,5431,398 claims
Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Synjardy, Tradjenta$1,986$1,311,5221,443 claims
AstraZenecaFarxiga$1,937$430,538545 claims
MerckJanumet Xr, Janumet, Januvia$1,631$148,747180 claims
AbbVieSynthroid$252$117,8521,585 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$1,079$106,914442 claims
BayerKerendia$2,540$56,93953 claims
Radius Health, Inc.Tymlos$142$40,84015 claims
AmgenProlia$2,013,306$21,00112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

Other endocrinology, diabetes & metabolism in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →